Back to Search
Start Over
Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy
- Source :
- Journal of human hypertension. 18(6)
- Publication Year :
- 2004
-
Abstract
- Hypertension is a major risk factor for morbidity and mortality. Plasma catecholamines are linked to the pathogenesis of hypertension. Pharmacological intervention, including treatment with beta-blockers, reduces cardiovascular mortality and morbidity. In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the angiotensin receptor blocker losartan significantly reduced cardiovascular end points compared to the beta-blocker atenolol. Thus, for the first time, one drug was shown to be superior to another in hypertension. The present substudy examined the effects of atenolol vs losartan treatment on plasma catecholamines at rest and during hyperinsulinaemia in a cohort of 86 LIFE patients. Plasma adrenaline increased significantly from placebo treatment at baseline to year 1 of treatment (P
- Subjects :
- Male
medicine.medical_specialty
Angiotensin receptor
Time Factors
medicine.drug_class
Left ventricular hypertrophy
Losartan
Muscle hypertrophy
Catecholamines
Internal medicine
Internal Medicine
medicine
Humans
Risk factor
Beta blocker
Antihypertensive Agents
Aged
Aged, 80 and over
business.industry
Middle Aged
Atenolol
medicine.disease
Angiotensin II
Endocrinology
Hypertension
Cardiology
Female
Hypertrophy, Left Ventricular
business
medicine.drug
Follow-Up Studies
Subjects
Details
- ISSN :
- 09509240
- Volume :
- 18
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Journal of human hypertension
- Accession number :
- edsair.doi.dedup.....3bdf7fe18d50eab9852bf417bef4f2c8